Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin with EPEM for Older Untreated Hodgkin Lymphoma
NCT03576378Phase 2Active, not recruiting
- Sponsor
- GELTAMO
- Start
- Aug 2018
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by GELTAMO. Started Aug 2018; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03576378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576378.